Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry

Nakaya, Aya; Tanaka, Hirokazu; Yano, Hideo; Ohta, Kensuke; Shibayama, Hirohiko; Kohara, Takae; Kanda, Junya; Shindo, Masami; Shimura, Yuji; Kosugi, Satoru; Kida, Toru; Kaneko, Hitomi; Imada, Kazunori; Karasuno, Takahiro; Matsuda, Mitsuhiro; Iida, Masato; Adachi, Yoko; Fuchida, Shin‐ichi; Uoshima, Nobuhiko; Uchiyama, Hitoji; Takahashi, Ryoichi; Matsui, Toshimitsu; Wada, Katsuya; Kiyota, Miki; Shimazaki, Chihiro; Hino, Masayuki; Kuroda, Junya; Kanakura, Yuzuru; Takaori‐Kondo, Akifumi; Nomura, Shosaku; Matsumura, Itaru; Investigators, Kansai Myeloma Forum

doi:10.1007/s12185-020-02961-3

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 25% of solitary plasmacytoma cases progress to MM within 5 years, 4 with a median time to progression of 10.5 months for SBP and 18.6 months for EMP. 5 Systemic examinations are necessary to monitor disease progression, as prognosis significantly worsens when accompanied by MM, resulting in a median survival time of merely 6.7 months. 4 Early identification of patients with plasmacytomas and those at risk of progressing to MM is crucial for appropriate management.…”

Section: Introductionmentioning

confidence: 99%

“…Intracranial plasmacytoma commonly involves the skull base, meninges, and brain but lacks specific imaging features. Approximately 25% of solitary plasmacytoma cases progress to MM within 5 years, 4 with a median time to progression of 10.5 months for SBP and 18.6 months for EMP 5 . Systemic examinations are necessary to monitor disease progression, as prognosis significantly worsens when accompanied by MM, resulting in a median survival time of merely 6.7 months 4 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases

Feng,

Zhang,

Qiu

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundIntracranial plasmacytomas are rare tumors arising from plasma cells with approximately half of the cases progressing to multiple myeloma (MM). However, there is a lack of comprehensive clinical cohort analysis on the clinical and pathological features, progression, and outcomes of intracranial plasmacytomas.MethodsA retrospective analysis of 190 cases was conducted, combining data from 38 cases in a single institution and 152 cases from the literature. Patient demographics, clinical presentations, tumor locations, imaging features, surgical treatments, and follow‐up outcomes were collected and analyzed. Survival analysis and Cox regression analysis were performed to identify prognostic factors.ResultsA total of 190 intracranial plasmacytoma patients with an average age of 55.4 years were included in the study. The preoperative misdiagnosis ratio was high at 55.3%, and 59.7% of the tumors affected the calvaria convexity, compared to 40.3% located at the skull base. Resection and biopsy were achieved in 72.4% and 27.6% patients, respectively. Among them, 34.2% (65/190) of patients were initially diagnosed with MM with intracranial plasmacytoma as their first presentation (MM‐IPFP), while 63.2% (120/190) of patients were diagnosed with solitary intracranial plasmacytoma (SIP), including 61 extramedullary plasmacytomas and 59 solitary bone plasmacytomas. In the SIP group, 22.4% (24/107) of patients experienced disease progression leading to the development of MM during a median follow‐up time of 42.6 months (range 1–230 months). Multivariate analysis unveiled that radiotherapy (HR, 0.05; 95% CI, 0.00–0.87; p = 0.04), not surgery, was a protective prognostic factor for overall survival in MM‐IPFP patients. Comparison between the SIP progression group and non‐progression group revealed a significant difference of Ki‐67 index (non‐progression vs. SIP progression, 8.82% ± 7.03 vs. 16.5% ± 10.5, p < 0.05). AUC analysis determined that a cutoff value of 9.0% was the best predictor of SIP progression, with an area under the curve of 0.712.ConclusionsThis retrospective clinical analysis highlights the potential role of radiotherapy, rather than surgical resection, in improving the outcomes of intracranial plasmacytoma. Additionally, the Ki‐67 index is identified as a valuable marker for predicting disease progression. This would provide some evidence for the paradigm of diagnosis and treatment modalities for intracranial plasmacytomas from the large cohort.

show abstract

Section: Introductionmentioning

confidence: 99%